Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enabling earlier detection and personalized screening.